Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI03258889

Publication Date:

March 5, 2025

Pages:

102

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Recombinant Human Follicle-stimulating Hormone market size is predicted to grow from US$ 1185 million in 2025 to US$ 1663 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031.
Recombinant Human Follicle-Stimulating Hormone (r-hFSH) is a biotechnologically produced hormone that plays a crucial role in the human reproductive system. It is a synthetic form of the naturally occurring follicle-stimulating hormone (FSH), which is produced by the anterior pituitary gland in the brain. FSH is essential for the regulation of the female and male reproductive systems and is involved in processes like ovarian follicle development, sperm production, and the maturation of reproductive cells.
Increasing Demand for Assisted Reproductive Technologies (ART): The growing acceptance of ART, including in vitro fertilization (IVF), is driving the demand for r-hFSH. ART is used by individuals and couples to address infertility issues, and r-hFSH plays a vital role in controlled ovarian stimulation.
Advancements in ART Procedures: Ongoing advancements in ART procedures are leading to increased use of r-hFSH. These procedures continue to improve success rates, which further fuels demand.
Expanded Indications: The use of r-hFSH is being explored for a broader range of indications, including for individuals with specific hormonal imbalances or other medical conditions that affect reproductive health.
Personalized Medicine: Tailoring treatment regimens to individual patients is gaining importance. Clinicians are increasingly using r-hFSH in personalized fertility treatment plans, optimizing the chances of success while minimizing side effects.
Global Expansion: The use of r-hFSH is expanding globally as countries invest in reproductive healthcare infrastructure. Emerging markets are showing increased demand for fertility treatments and related products.
The 鈥淩ecombinant Human Follicle-stimulating Hormone Industry Forecast鈥� looks at past sales and reviews total world Recombinant Human Follicle-stimulating Hormone sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human Follicle-stimulating Hormone sales for 2025 through 2031. With Recombinant Human Follicle-stimulating Hormone sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Follicle-stimulating Hormone industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human Follicle-stimulating Hormone landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Recombinant Human Follicle-stimulating Hormone portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant Human Follicle-stimulating Hormone market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Follicle-stimulating Hormone and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Follicle-stimulating Hormone.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Follicle-stimulating Hormone market by product type, application, key players and key regions and countries.
Segmentation by Type:
75IU
150IU
Others
Segmentation by Application:
Infertility Treatment
Assisted Reproductive Technology
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Ferring
Livzon
Gedeon Richter
GenSci
Teva
ChangChun High & New Technology
ABL
Scripps Laboratories
Alphamab Oncology
Hunan Jingfeng Pharmaceutical
Qilu Pharmaceutical
Beijing SL Pharmaceutical

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size (2020-2031)
2.1.2 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Recombinant Human Follicle-stimulating Hormone by Country/Region (2020, 2024 & 2031)
2.2 Recombinant Human Follicle-stimulating Hormone Segment by Type
2.2.1 75IU
2.2.2 150IU
2.2.3 Others
2.3 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Type
2.3.1 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Recombinant Human Follicle-stimulating Hormone Segment by Application
2.4.1 Infertility Treatment
2.4.2 Assisted Reproductive Technology
2.5 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Application
2.5.1 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Player
3.1 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Recombinant Human Follicle-stimulating Hormone Revenue by Player (2020-2025)
3.1.2 Global Recombinant Human Follicle-stimulating Hormone Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Recombinant Human Follicle-stimulating Hormone Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Recombinant Human Follicle-stimulating Hormone by Region
4.1 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Region (2020-2025)
4.2 Global Recombinant Human Follicle-stimulating Hormone Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size Growth (2020-2025)
4.4 APAC Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size Growth (2020-2025)
4.5 Europe Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Country (2020-2025)
5.2 Americas Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Type (2020-2025)
5.3 Americas Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Region (2020-2025)
6.2 APAC Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Type (2020-2025)
6.3 APAC Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Country (2020-2025)
7.2 Europe Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Type (2020-2025)
7.3 Europe Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Human Follicle-stimulating Hormone by Region (2020-2025)
8.2 Middle East & Africa Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Forecast
10.1 Global Recombinant Human Follicle-stimulating Hormone Forecast by Region (2026-2031)
10.1.1 Global Recombinant Human Follicle-stimulating Hormone Forecast by Region (2026-2031)
10.1.2 Americas Recombinant Human Follicle-stimulating Hormone Forecast
10.1.3 APAC Recombinant Human Follicle-stimulating Hormone Forecast
10.1.4 Europe Recombinant Human Follicle-stimulating Hormone Forecast
10.1.5 Middle East & Africa Recombinant Human Follicle-stimulating Hormone Forecast
10.2 Americas Recombinant Human Follicle-stimulating Hormone Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.2.2 Canada 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.2.3 Mexico 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.2.4 Brazil 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.3 APAC Recombinant Human Follicle-stimulating Hormone Forecast by Region (2026-2031)
10.3.1 China Recombinant Human Follicle-stimulating Hormone 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.3.3 Korea 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.3.4 Southeast Asia 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.3.5 India 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.3.6 Australia 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.4 Europe Recombinant Human Follicle-stimulating Hormone Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.4.2 France 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.4.3 UK 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.4.4 Italy 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.4.5 Russia 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.5 Middle East & Africa Recombinant Human Follicle-stimulating Hormone Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.5.2 South Africa 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.5.3 Israel 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.5.4 Turkey 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
10.6 Global Recombinant Human Follicle-stimulating Hormone Forecast by Type (2026-2031)
10.7 Global Recombinant Human Follicle-stimulating Hormone Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Recombinant Human Follicle-stimulating Hormone Forecast
11 Key Players Analysis
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Recombinant Human Follicle-stimulating Hormone Product Offered
11.1.3 Merck Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Merck Main Business Overview
11.1.5 Merck Latest Developments
11.2 Ferring
11.2.1 Ferring Company Information
11.2.2 Ferring Recombinant Human Follicle-stimulating Hormone Product Offered
11.2.3 Ferring Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Ferring Main Business Overview
11.2.5 Ferring Latest Developments
11.3 Livzon
11.3.1 Livzon Company Information
11.3.2 Livzon Recombinant Human Follicle-stimulating Hormone Product Offered
11.3.3 Livzon Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Livzon Main Business Overview
11.3.5 Livzon Latest Developments
11.4 Gedeon Richter
11.4.1 Gedeon Richter Company Information
11.4.2 Gedeon Richter Recombinant Human Follicle-stimulating Hormone Product Offered
11.4.3 Gedeon Richter Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Gedeon Richter Main Business Overview
11.4.5 Gedeon Richter Latest Developments
11.5 GenSci
11.5.1 GenSci Company Information
11.5.2 GenSci Recombinant Human Follicle-stimulating Hormone Product Offered
11.5.3 GenSci Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 GenSci Main Business Overview
11.5.5 GenSci Latest Developments
11.6 Teva
11.6.1 Teva Company Information
11.6.2 Teva Recombinant Human Follicle-stimulating Hormone Product Offered
11.6.3 Teva Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Teva Main Business Overview
11.6.5 Teva Latest Developments
11.7 ChangChun High & New Technology
11.7.1 ChangChun High & New Technology Company Information
11.7.2 ChangChun High & New Technology Recombinant Human Follicle-stimulating Hormone Product Offered
11.7.3 ChangChun High & New Technology Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 ChangChun High & New Technology Main Business Overview
11.7.5 ChangChun High & New Technology Latest Developments
11.8 ABL
11.8.1 ABL Company Information
11.8.2 ABL Recombinant Human Follicle-stimulating Hormone Product Offered
11.8.3 ABL Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 ABL Main Business Overview
11.8.5 ABL Latest Developments
11.9 Scripps Laboratories
11.9.1 Scripps Laboratories Company Information
11.9.2 Scripps Laboratories Recombinant Human Follicle-stimulating Hormone Product Offered
11.9.3 Scripps Laboratories Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Scripps Laboratories Main Business Overview
11.9.5 Scripps Laboratories Latest Developments
11.10 Alphamab Oncology
11.10.1 Alphamab Oncology Company Information
11.10.2 Alphamab Oncology Recombinant Human Follicle-stimulating Hormone Product Offered
11.10.3 Alphamab Oncology Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Alphamab Oncology Main Business Overview
11.10.5 Alphamab Oncology Latest Developments
11.11 Hunan Jingfeng Pharmaceutical
11.11.1 Hunan Jingfeng Pharmaceutical Company Information
11.11.2 Hunan Jingfeng Pharmaceutical Recombinant Human Follicle-stimulating Hormone Product Offered
11.11.3 Hunan Jingfeng Pharmaceutical Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Hunan Jingfeng Pharmaceutical Main Business Overview
11.11.5 Hunan Jingfeng Pharmaceutical Latest Developments
11.12 Qilu Pharmaceutical
11.12.1 Qilu Pharmaceutical Company Information
11.12.2 Qilu Pharmaceutical Recombinant Human Follicle-stimulating Hormone Product Offered
11.12.3 Qilu Pharmaceutical Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Qilu Pharmaceutical Main Business Overview
11.12.5 Qilu Pharmaceutical Latest Developments
11.13 Beijing SL Pharmaceutical
11.13.1 Beijing SL Pharmaceutical Company Information
11.13.2 Beijing SL Pharmaceutical Recombinant Human Follicle-stimulating Hormone Product Offered
11.13.3 Beijing SL Pharmaceutical Recombinant Human Follicle-stimulating Hormone Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Beijing SL Pharmaceutical Main Business Overview
11.13.5 Beijing SL Pharmaceutical Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.